Private equity player Celtic bankrolls new Swiss antibody-drug conjugate company
This article was originally published in Scrip
Executive Summary
Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, is leveraging the power of a technology platform owned by portfolio company Spirogen to create a new company focused on antibody drug conjugate (ADC) products. Alongside other Spirogen shareholders, Celtic Therapeutics is earmarking up to $50million for Lausanne, Switzerland-based ADC Therapeutics to develop a pipeline of 10 proprietary antibody drug conjugate oncology development programmes, targeting multiple major cancers, including prostate, renal, breast, lung and blood cancers.